Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: KRT009
MIFTS: 51

Keratosis

Categories: Skin diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Keratosis

About this section

MalaCards integrated aliases for Keratosis:

Name: Keratosis 11 43 14 16 71 75
Actinic Keratosis 71
Hyperkeratosis 71

Classifications:

MalaCards categories:
Anatomical: Skin diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 11 DOID:161
MeSH 43 D007642
NCIt 49 C34747
SNOMED-CT 68 254666005
UMLS 71 C0022593 C0022602 C0870082
Sources

Summaries for Keratosis

About this section

Disease Ontology: 11 A skin disease characterized by growth of keratin on the skin or mucous membranes.

MalaCards based summary: Keratosis, also known as actinic keratosis, is related to keratosis, seborrheic and keratosis pilaris atrophicans, and has symptoms including pruritus, exanthema and trichorrhexis invaginata. An important gene associated with Keratosis is CTSC (Cathepsin C), and among its related pathways/superpathways are Nervous system development and Keratinization. The drugs Hydrogen peroxide and Bacitracin have been mentioned in the context of this disorder. Affiliated tissues include skin, kidney and liver, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia: 75 Keratosis (from kerat- + -osis) is a growth of keratin on the skin or on mucous membranes stemming from... more...
Sources

Related Diseases for Keratosis

About this section

Diseases related to Keratosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 582)
# Related Disease Score Top Affiliating Genes
1 keratosis, seborrheic 33.1 TP53 PIK3CA KRT10 FGFR3
2 keratosis pilaris atrophicans 33.1 SAT1 MBTPS2 LRP1
3 actinic keratosis 33.0 TP53 LORICRIN KRT10 FLG
4 keratosis follicularis spinulosa decalvans 33.0 SAT1 MBTPS2 LRP1
5 keratosis follicularis spinulosa decalvans, autosomal dominant 32.4 TGM1 MBTPS2
6 punctate palmoplantar keratoderma 32.4 SERPINB7 MBTPS2 GJB2
7 palmoplantar keratoderma, epidermolytic 32.0 SERPINB7 KRT9 KRT86 KRT16 KRT10 KRT1
8 acrokeratosis verruciformis 31.9 KRT1 ATP2A2
9 clear cell acanthoma 31.9 KRT10 FLG
10 olmsted syndrome, x-linked 31.8 SAT1 MBTPS2
11 palmoplantar keratoderma, nonepidermolytic 31.8 KRT9 KRT16 KRT1
12 acrokeratoderma, hereditary papulotranslucent 31.7 KRT9 KRT1 GJB2
13 mutilating palmoplantar keratoderma with periorificial keratotic plaques 31.7 SERPINB7 MBTPS2 LORICRIN
14 cholesteatoma of middle ear 31.6 KRT16 KRT10 GJB2 FLG
15 peeling skin syndrome 31.6 TGM1 LORICRIN FLG
16 erythrokeratodermia variabilis et progressiva 1 31.5 TGM1 SERPINB7 LORICRIN KRT10 KRT1 GJB3
17 ichthyosis vulgaris 31.5 TGM1 LORICRIN KRT10 KRT1 FLG
18 palmoplantar keratosis 31.4 SERPINB7 LORICRIN KRT9 KRT16 KRT10 KRT1
19 bowen's disease 31.3 KRT16 KRT10
20 vohwinkel syndrome 31.2 TGM1 LORICRIN KRT10 GJB3 GJB2
21 skin benign neoplasm 31.1 TP53 KRT1 FGFR3
22 alopecia 31.1 MBTPS2 KRT86 FLG
23 lichen planus 31.0 TP53 KRT16 KRT10 KRT1 FLG
24 papilloma 31.0 TP53 KRT10 KRT1 FLG FGFR3
25 basal cell carcinoma 30.9 TP53 KRT16 KRT10 KRT1
26 autosomal dominant epidermolytic ichthyosis 30.8 KRT10 KRT1
27 acanthoma 30.7 TP53 PIK3CA KRT10 KRT1 FGFR3
28 keratoacanthoma 30.6 TP53 PIK3CA KRT16 KRT10 FLG
29 benign chronic pemphigus 30.5 SERPINB7 KRT10 ATP2A2
30 nevus, epidermal 30.4 PIK3CA KRT10 KRT1 GJB2 FGFR3 ATP2A2
31 ichthyosis follicularis atrichia photophobia syndrome 30.3 MBTPS2 GJB2
32 large cell acanthoma 30.3 TP53 KRT10
33 cutaneous ganglioneuroma 30.3 PIK3CA FGFR3
34 human papillomavirus infectious disease 30.3 TP53 PIK3CA FLG
35 ainhum 30.1 LORICRIN GJB2
36 keratitis-ichthyosis-deafness syndrome, autosomal dominant 30.1 TGM1 GJB2
37 ichthyosis, annular epidermolytic, 1 30.1 KRT10 KRT1
38 contact dermatitis 30.1 LORICRIN KRT16 FLG
39 porokeratosis 30.0 TP53 LORICRIN KRT16 KRT10 KRT1 GJB2
40 knuckle pads 30.0 KRT9 GJB2
41 epidermolysis bullosa dystrophica 29.9 KRT9 KRT1 FLG
42 ectodermal dysplasia 29.8 KRT16 GJB3 GJB2 FGFR3
43 ichthyosis 29.8 TGM1 MBTPS2 LORICRIN KRT86 KRT16 KRT10
44 psoriasis 29.7 TGM1 LORICRIN KRT16 KRT10 KRT1 KLK8
45 hair disease 29.7 MBTPS2 LORICRIN KRT86 FLG
46 keratoderma, palmoplantar, with deafness 29.7 GJB3 GJB2
47 ichthyosis, x-linked 29.7 TGM1 MBTPS2 KRT1 FLG
48 bart-pumphrey syndrome 29.6 GJB3 GJB2
49 epidermolysis bullosa 29.6 TP53 LORICRIN KRT16 KRT10 KRT1 FLG
50 skin disease 29.4 TP53 TGM1 PIK3CA LORICRIN KRT9 KRT16

Comorbidity relations with Keratosis via Phenotypic Disease Network (PDN):


Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Keratosis, Seborrheic

Graphical network of the top 20 diseases related to Keratosis:



Diseases related to Keratosis
Sources

Symptoms & Phenotypes for Keratosis

About this section

UMLS symptoms related to Keratosis:


pruritus; exanthema; trichorrhexis invaginata

MGI Mouse Phenotypes related to Keratosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 ATP2A2 CTSC FGFR3 GJB2 GJB3 KLK8
2 growth/size/body region MP:0005378 10.06 ATP2A2 CTSC FGFR3 GJB2 GJB3 KLK8
3 neoplasm MP:0002006 9.87 ATP2A2 FGFR3 KRT10 KRT9 PIK3CA SAT1
4 immune system MP:0005387 9.73 ATP2A2 CTSC FGFR3 GJB2 KLK8 KRT1
5 integument MP:0010771 9.5 ATP2A2 CTSC FGFR3 GJB2 GJB3 KRT1
Sources

Drugs & Therapeutics for Keratosis

About this section

Drugs for Keratosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrogen peroxide Approved, Vet_approved Phase 4 7722-84-1 784
2
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 10909430
3
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
4
Prilocaine Approved Phase 4 721-50-6 4906
5
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
6
Menthol Approved, Experimental Phase 4 1490-04-6, 2216-51-5, 15356-60-2 1254 16666 165675
7
Tirbanibulin Approved, Investigational Phase 4 897016-82-9 23635314
8
Diclofenac Approved, Vet_approved Phase 4 15307-86-5, 15307-79-6 3033
9
Aminolevulinic acid Approved Phase 4 106-60-5 137
10
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
11
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
12
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8 5280382 445354
13
Protoporphyrin Experimental Phase 4 553-12-8
14 Radiation-Protective Agents Phase 4
15 Lidocaine, Prilocaine Drug Combination Phase 4
16 Anti-Bacterial Agents Phase 4
17 Anti-Infective Agents Phase 4
18 Anti-Infective Agents, Local Phase 4
19 Protective Agents Phase 4
20 Anti-Arrhythmia Agents Phase 4
21 Sodium Channel Blockers Phase 4
22 Anesthetics, Local Phase 4
23 Diuretics, Potassium Sparing Phase 4
24 Viscosupplements Phase 4
25 Retinol palmitate Phase 4
26 Antirheumatic Agents Phase 4
27 Cyclooxygenase Inhibitors Phase 4
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4
29 Analgesics, Non-Narcotic Phase 4
30 Anti-Inflammatory Agents Phase 4
31 Analgesics Phase 4
32 Photosensitizing Agents Phase 4
33 Dermatologic Agents Phase 4
34 Pharmaceutical Solutions Phase 4
35 Methyl 5-aminolevulinate Phase 4
36 Adjuvants, Immunologic Phase 4
37 interferons Phase 4
38 Immunologic Factors Phase 4
39 Emollients Phase 4
40
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
41
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
42
Dimethyl sulfoxide Approved, Vet_approved Phase 3 67-68-5 679
43
Selenium Approved, Investigational, Vet_approved Phase 3 7783-07-5, 7782-49-2 533
44
Selenious acid Approved, Investigational Phase 3 14124-67-5, 7783-00-8 1091
45
Fluorouracil Approved Phase 3 51-21-8 3385
46 Keratolytic Agents Phase 3
47 Antifungal Agents Phase 3
48
Salicylates Phase 3
49 Trace Elements Phase 3
50 Micronutrients Phase 3

Interventional clinical trials:

(show top 50) (show all 337)
# Name Status NCT ID Phase Drugs
1 Topical Ingenol Mebutate Versus 5% 5-fluorouracil Versus 5% Imiquimod Versus Photodynamic Therapy in Treatment of Actinic Keratosis: a Multi-centre Randomized Efficacy and Cost-effectiveness Study Unknown status NCT02281682 Phase 4 Imiquimod;5-fluorouracil;Ingenol mebutate
2 Comparative Intraindividual Study, About the Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between Acid Methyl Aminolevulinate Cream and Aminolevulinic Gel Unknown status NCT02647151 Phase 4 METHYLAMINOLEVULINATE HYDROCHLORIDE;AMINOLEVULINIC ACID HYDROCHLORIDE
3 A Randomised Double-blind Parallel-group Study to Evaluate the Long-term Effects of Eryfotona AK-NMSC® Cream in the Treatment of Cancerization Field in Patients With Actinic Keratosis. Unknown status NCT01656226 Phase 4
4 An Investigator-Initiated Study to Assess the Safety and Efficacy of Imiquimod 3.75% Cream When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands and Forearms Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
5 A Double-blind, Randomized, Placebo-controlled, 2-way Crossover Study to Assess the Potential Effect of Topically Applied Imiquimod Cream on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4 Imiquimod cream 3.75%;Placebo cream
6 An Open-Label Study Assessing Subject Satisfaction With A-101 Hydrogen Peroxide Topical Solution, 40% (w/w) Treatment for Seborrheic Keratoses of the Face, Neck, and Decolletage Completed NCT03487588 Phase 4 A-101 Topical Solution
7 A Randomized, Parallel-Group, Vehicle-Controlled, Double-Blind Study of Topical Imiquimod 5% Cream Used as an Adjunct to Cryotherapy in the Management of Actinic Keratoses, With a Long-Term (1 Year) Follow-Up Completed NCT00110682 Phase 4 Imiquimod used as an adjunct to cryotherapy
8 Treatment of AKs With Daylight-PDT: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
9 A Randomized Right/Left Clinical Trial to Evaluate the Use of Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy Completed NCT00695578 Phase 4 Biafine;Polysporin
10 Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population Completed NCT00696488 Phase 4 Fluorouracil 0.5%
11 Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents Completed NCT03279328 Phase 4 Topical Steroid Ointment;Skin Barrier Moisturier
12 A Randomized, Open-label, Assessor-blinded, Split-face Study of Imiquimod 5% Cream Applied After Cryotherapy of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
13 An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses Completed NCT00377273 Phase 4 fluorouracil cream 0.5%
14 Prospective, Controlled and Monocentric Study to Evaluate the Effects of Topical 3% Diclofenac in 2.5% Hyaluronic Acid Gel on Tumor Metabolism in the Treatment of Actinic Keratoses in Immunocompetent and Immunocompromised Patients Completed NCT01935531 Phase 4 3% diclofenac in 2.5% hyaluronic acid gel
15 A Randomized, Evaluator-blinded, Bilateral Comparison of the Treatment of Facial Actinic Keratoses Using Combination Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Different Incubation Times Completed NCT02622594 Phase 4 Aminolevulinic Acid (ALA)
16 An Investigator-Initiated Study to Assess the Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands Completed NCT02251652 Phase 4 Ingenol Mebutate
17 A Comparison of the Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy According to the Density of Ablative Laser Channel in the Treatment of Actinic Keratosis Completed NCT03731988 Phase 4 lidocaine/prilocaine (5%) application;MAL application
18 A Multi-center, OPen, InvEstigator Initiated Phase IV Clinical TRial to Evaluate the Efficacy and SaFety of Ingenol Mebutate Gel 0.015% on Face and Scalp & 0.05% on Trunk and Extremities in KorEan Patient With ACtinic KeraTosis (PERFECT) Completed NCT02716714 Phase 4 ingenol mebutate gel 0.015%;ingenol mebutate gel 0.05%
19 Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp (LEIDA) Completed NCT00777127 Phase 4 Imiquimod;Diclofenac
20 A Randomized Study to Evaluate the Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization Compared to Cryotherapy Completed NCT02990221 Phase 4 Ingenol mebutate
21 Photodynamic Therapy of Actinic Keratosis of the Face and Scalp With and Without Prior Curettage Completed NCT03697590 Phase 4 No curettage;Curettage
22 Prospective, Randomized, Controlled, Multicenter, Two-armed, Study Comparing Daylight Photodynamic Therapy Using MAL With Cryosurgery for the Treatment and Prophylaxis of Actinic Keratoses in Photodamaged Skin of the Face Completed NCT02736760 Phase 4 Daylight photodynamic therapy using Methylaminolevulinate (MAL)
23 A Phase 4 Trial Comparing the Cumulative Incidence of SCC After Treatment With Ingenol Mebutate and Imiquimod for Multiple Actinic Keratoses on Face and Scalp. A Multi-centre, Randomised, Two-arm, Open Label, Active-controlled, Parallel Group, 36-month Trial Completed NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
24 UCI 14-92 / HS#2015-1889: Phase IV Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses Completed NCT03327831 Phase 4 Aminolevulinic Acid
25 A Randomised Double Blind, Placebo Controlled Study of the Efficacy of Topical Menthol for Pain Relief During Topical Photodynamic Therapy Completed NCT02984072 Phase 4 Menthol;Aqueous Cream
26 Open-Label Safety and Pharmacokinetic Study of AldaraTM (Imiquimod) Cream, 5% for One, Two, or Three Treatment Cycles to Surface Areas Greater Than 25 cm2 With Actinic Keratosis Completed NCT00116649 Phase 4 imiquimod cream
27 Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Upper Extremities Completed NCT00115154 Phase 4 Aldara (imiquimod) cream, 5%
28 Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® PDT Completed NCT01000636 Phase 4
29 Frequency and Intensity of Local Reactions in Patients Treated With 4% 5-FU vs 4% 5-FU Associated With an Emollient Cream: a Randomised, Controlled Clinical Trial Completed NCT04875026 Phase 4 5-fluorouracil 4% (Tolak)
30 Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp Completed NCT02406014 Phase 4 Ingenol Mebutate Gel, 0.015%;Diclofenac sodium gel 3%
31 Daylight Mediated Photodynamic Therapy for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) Completed NCT02464709 Phase 4 Aminolevulinic Acid;Methyl 5-aminolevulinate
32 Clinical and Dermoscopic Evaluation of Long-pulsed 1064 nm Nd-YAG Laser Versus Trichloroacetic Acid 20% in Treatment of Keratosis Pilaris Completed NCT04797663 Phase 4 TCA 20%
33 Comparison of the Efficacy and Tolerability of Solaraze for 3 vs. 6 Months in Patients With Mild to Moderate Actinic Keratosis Located at the Face and Head Completed NCT00204542 Phase 4 Diclofenac
34 Subject Reported Outcomes on Satisfaction, Safety and Efficacy With Luxerm® in the Field-directed Treatment of Thin or Non-hyperkeratotic and Non-pigmented Actinic Keratosis of the Face or the Scalp Completed NCT03511326 Phase 4 Methyl Aminolaevulinate 16% Cream
35 A Pilot Prospective Clinical Trial to Evaluate the Efficacy and Safety of Large-Scale, Field-Directed Topical Therapy of Actinic Keratosis of the Chest With Ingenol Mebutate 0.015% Completed NCT02446223 Phase 4 Inggenol Mebutate 0.015%
36 Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream Completed NCT04842422 Phase 4 Imiquimod 3.75% Cream
37 Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp With Respect to the Risk of Progression to In-situ and Invasive Squamous Cell Carcinoma Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
38 Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of Actinic Keratosis on the Face in Solid Organ Transplant Recipients Completed NCT02866695 Phase 4 ingenol mebutate gel 0.015%
39 Aminolevulinic Acid-photodynamic Therapy for Facial Actinic Keratosis Treatment and Prevention: A Long-term (3 Years) Follow-up of Prospective, Randomized, Multicenter-clinical Trial Recruiting NCT03642535 Phase 4 ALA
40 A Phase 4, Multi-centre, Randomized, Evaluator-blinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Evaluate the Long-term Safety of Tirbanibulin 10 mg/g Ointment and Diclofenac Sodium 3% Gel for the Treatment of Adult Patients With Actinic Keratosis on the Face or Scalp Recruiting NCT05387525 Phase 4 Tirbanibulin (Klisyri®) 10 mg/g ointment;Diclofenac Sodium 3% Gel
41 Safety and Efficacy of Photodynamic Therapy With Aminolevulinic Acid 10% Topical Gel Activated by Red Light Versus Aminolevulinic Acid 20% Topical Solution Activated by Blue Light for the Treatment of Actinic Keratosis on the Upper Extremities: A Blinded Randomized Study Not yet recruiting NCT05359419 Phase 4
42 A Study to Investigate the Effect of Different Durations of Ameluz Application on Response to Treatment of Acral Actinic Keratoses Suspended NCT03963102 Phase 4 Ameluz
43 Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study Terminated NCT00944216 Phase 4 Salkera Emollient Foam
44 An Exploratory, Open-label Study of Sequential Field-directed Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Terminated NCT01203878 Phase 4 Photodynamic therapy;Imiquimod
45 Topical Imiquimod 5% Cream Therapy Versus Photodynamic Therapy With Methyl-aminolaevulinate 16% Cream of Actinic Keratoses in Organ Transplant Recipients Terminated NCT01538901 Phase 4 imiquimod 5% cream
46 A RANDOMIZED, DOUBLE BLIND, MULTI-CENTER CLINICAL STUDY TO TEST THE SAFETY AND EFFICACY OF T4N5 LIPOSOME LOTION ON PATIENTS WITH XERODERMA PIGMENTOSUM IN THE PROTECTION AGAINST ACTINIC KERATOSES Unknown status NCT00002811 Phase 3 liposomal T4N5 lotion
47 Phase III Comparative Study About the Use of 5% 5-fluorouracil Cream Versus Its Utilization as Agent for Sequential Superficial Peeling in the Treatment of Advanced Photoaging Unknown status NCT01405144 Phase 3 5-fluoruracil
48 An Open-Label Study of the Safety of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face. Completed NCT02667288 Phase 3 A-101 Solution
49 A Randomized, Double-Blind, Vehicle-Controlled, PArallel Group Study of the Safety and Effectiveness of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face. Completed NCT02667275 Phase 3 A-101 Solution
50 A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Safety and Effectiveness of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face. Completed NCT02667236 Phase 3 A-101 Solution

Search NIH Clinical Center for Keratosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Diclofenac
Diclofenac Potassium
Diclofenac Sodium
Fluorouracil
Masoprocol

Cochrane evidence based reviews: keratosis

Sources

Genetic Tests for Keratosis

About this section
Sources

Anatomical Context for Keratosis

About this section

Organs/tissues related to Keratosis:

MalaCards : Skin, Kidney, Liver, Eye, Lung, Cervix, Breast
Sources

Publications for Keratosis

About this section

Articles related to Keratosis:

(show top 50) (show all 6323)
# Title Authors PMID Year
1
Epidermal expression of serine protease, neuropsin (KLK8) in normal and pathological skin samples. 53 62
12147714 2002
2
Relationship between actinic keratosis and malignant skin lesions on the eyelid. 62
35170648 2023
3
Photodynamic therapy with light emitting fabrics: a review. 62
34797414 2022
4
Anti-MDA5 and anti-SSA/Ro52 antibodies double-positive dermatomyositis overlapping with rheumatoid arthritis-associated interstitial lung disease: A case report. 62
36029141 2022
5
Saliva-based cell-free DNA and cell-free mitochondrial DNA in head and neck cancers have promising screening and early detection role. 62
36459078 2022
6
Comment on "follicular keratosis of the face in pediatric patients of color". 62
36468212 2022
7
Treatment of actinic keratosis: a systematic review. 62
36454335 2022
8
Prevalence of 13 polyomaviruses in actinic keratosis and matched healthy skin samples of immunocompetent individuals. 62
36457033 2022
9
Clonal-pattern Seborrheic Keratosis: Risk of Recurrence and Progression to Carcinoma. 62
36221316 2022
10
Seborrheic Keratosis With Malignant Transformation (Invasive or Noninvasive Squamous Cell Carcinoma Arising in Seborrheic Keratosis): A Clinicopathologic and Immunohistochemical Study of 11 Cases. 62
36395445 2022
11
Partial spontaneous regression in two cases of seborrheic keratosis. 62
35394070 2022
12
Keratosis follicularis spinulosa decalvans in a woman with XY karyotype. 62
36459468 2022
13
Keratinocyte Regnase-1, a down-regulator of skin inflammation, contributes to protection against tumor promotion by limiting COX-2 expression. 62
36470473 2022
14
Oral Lichen Planus: Associations Between Histomorphometric Characteristics and White and Red Lesions. 62
35579856 2022
15
Predictors of subsequent primary melanoma: a case-control study. 62
34825952 2022
16
Fractal Dimension and Radiomorphometric analysis of Orthopanoramic radiographs in patients with tobacco and areca nut associated oral mucosal lesions: A pilot in-vivo study in a North Indian cohort. 62
36055927 2022
17
Comparison of reflectance confocal microscopy and line-field optical coherence tomography for the identification of keratinocyte skin tumours. 62
36424847 2022
18
Hemodynamic changes during conventional and daylight photodynamic therapy of actinic keratoses - a randomized controlled trial. 62
35775704 2022
19
Innovative digital solution supporting sun protection and vitamin D synthesis by using satellite-based monitoring of solar radiation. 62
35870076 2022
20
Measurements of illuminance in simulated daylight photodynamic therapy. 62
35437865 2022
21
Computer Aided Diagnosis of Melanoma Using Deep Neural Networks and Game Theory: Application on Dermoscopic Images of Skin Lesions. 62
36430315 2022
22
KERATIN 17-related recessive atypical pachyonychia congenita with variable hair and tooth anomalies. 62
35676340 2022
23
"African" acral keratoderma: Further evidence for a single entity. A retrospective study of 42 patients. 62
36424301 2022
24
Cutaneous Squamous Cell Carcinoma and Mortality in End-Stage Renal Disease. 62
36403674 2022
25
Immunothrombotic Mechanisms Induced by Ingenol Mebutate Lead to Rapid Necrosis and Clearance of Anogenital Warts. 62
36362165 2022
26
Successful treatment of severe pityriasis rubra pilaris with secukinumab in a 3-year-old boy. 62
35906074 2022
27
Cutaneous Ganglioneuromas With Overlying Epidermal Hyperplasia: A Case Series Presentation and Proposal of Potential Etiopathogenesis. 62
35925148 2022
28
HPV42-associated Seborrhoeic Keratosis-like Lesion of the Cervix: First Reported Case With High-grade Morphology. 62
35072991 2022
29
Factors associated with severity of atopic dermatitis - a Finnish cross-sectional study. 62
35766133 2022
30
Controlled register-based study of road traffic accidents in 12,651 Finnish cancer patients during 2013-2019. 62
36397273 2022
31
Two Distinct Lesions of Inverted Follicular Keratosis of the Scalp: A Case Report. 62
36349066 2022
32
Cultural adaptation and validation of the quality of life questionnaire for patients with actinic keratosis (AKQoL-BR) to Brazilian Portuguese. 62
36137891 2022
33
Risk of squamous cell carcinoma in immunosuppressed patients with voriconazole-related actinic keratosis. 62
35986452 2022
34
Comment on "Guidelines of care for the management of actinic keratosis". 62
35724889 2022
35
Lichen planus-like keratosis: what do we know about it? 62
35775867 2022
36
Health state utility instruments in patients with keratinocyte cancer and actinic keratosis: a cross-sectional study. 62
35734826 2022
37
Fully home-based methyl aminolevulinate daylight photodynamic therapy for actinic keratosis of the face or scalp: A real life open study. 62
36184916 2022
38
Clinical Experience Using a Monofilament Fiber Cleansing and Debriding Technology for Various Skin Conditions. 62
36342736 2022
39
Loss-of-function mutations in CST6 cause dry skin, desquamation and abnormal keratosis without hypotrichosis. 62
36371786 2022
40
Reflectance confocal microscopy of facial neoplasms: Follicular involvement as a clue to diagnosis. 62
36321579 2022
41
Efficacy of two different methods of cold air analgesia for pain relief in PDT of actinic keratoses of the head region - a randomized controlled comparison study. 62
36336323 2022
42
Potential use of microwave technology in dermatology. 62
35699665 2022
43
The Copenhagen Actinic Keratosis Study (COAKS). A decentralised clinical trial to evaluate tolerability, safety and efficacy of daily field-directed topical treatment with cytosolic phospholipase A2 inhibitor, AVX001, in participants with actinic keratosis: protocol for a randomised controlled phase I/IIa trial. 62
36198452 2022
44
Commentary: Complete Clearance of Actinic Keratosis with Tirbanibulin Ointment 1% is not Correlated with the Severity of Local Skin Reactions. 62
36408376 2022
45
Pigmented Actinic Keratosis Versus In Situ Melanoma: PRAME May Be Helpful. 62
35925568 2022
46
Influence of serum vitamin D level in the response of actinic keratosis to ingenol mebutate. 62
36261393 2022
47
New onset of palmoplantar keratosis triggered by COVID-19 vaccination. 62
36239020 2022
48
Commentary: Impact of Prior Treatment in the Efficacy and Tolerability of Tirbanibulin Ointment 1% for Actinic Keratosis: Pooled Results from Two Phase III Studies. 62
36408373 2022
49
Profile of Tirbanibulin for the Treatment of Actinic Keratosis. 62
36408375 2022
50
Commentary: Emotional and Social/Functioning Impact of Actinic Keratosis on Individuals Living with the Condition: An Exploratory Qualitative Research Initiative in the US. 62
36408374 2022
Sources

Variations for Keratosis

About this section
Sources

Expression for Keratosis

About this section
Search GEO for disease gene expression data for Keratosis.
Sources

Pathways for Keratosis

About this section

Pathways related to Keratosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Nervous system development 66
Show member pathways
 13.01 TGM1 PIK3CA LORICRIN KRT9 KRT86 KRT16
2
Keratinization 66
Show member pathways
 11.81 TGM1 LORICRIN KRT9 KRT86 KRT16 KRT10
3
Burn wound healing 74
11.31 TP53 FLG FGFR3
4
Head and neck squamous cell carcinoma 74
11.2 TP53 PIK3CA FGFR3
5
NOTCH1 regulation of endothelial cell calcification 74
10.5 SAT1 FGFR3
Sources

GO Terms for Keratosis

About this section

Cellular components related to Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratin filament GO:0045095 9.76 KRT9 KRT86 KRT10 KRT1
2 intermediate filament GO:0005882 9.5 KRT9 KRT86 KRT16 KRT10 KRT1
3 cornified envelope GO:0001533 9.4 TGM1 LORICRIN KRT16 KRT10 KRT1 FLG

Biological processes related to Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament organization GO:0045109 9.86 KRT9 KRT86 KRT16 KRT1
2 establishment of skin barrier GO:0061436 9.85 KRT16 KRT1 FLG
3 keratinization GO:0031424 9.85 KRT1 KRT16 KRT86 LORICRIN TGM1
4 keratinocyte differentiation GO:0030216 9.65 TGM1 LORICRIN KRT16 KRT10 FLG
5 bone maturation GO:0070977 9.62 MBTPS2 FGFR3
6 peptide cross-linking GO:0018149 9.32 TGM1 LORICRIN KRT10 KRT1 FLG

Molecular functions related to Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of skin epidermis GO:0030280 9.32 LORICRIN KRT86 KRT10 KRT1 FLG
2 structural molecule activity GO:0005198 9.26 KRT9 KRT16 KRT10 FLG
Sources

Sources for Keratosis

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....